GLP-2T

Overview

GLP-2T is a research-grade reference compound within the dual GIP/GLP-1 receptor agonist class. Chemically characterized as a 39-amino-acid synthetic peptide incorporating structural elements of both GIP and GLP-1, with a C20 fatty-acid diacid side chain for extended half-life, the compound has been studied in extensive preclinical and clinical research for its role in dual-receptor pharmacology and metabolic pathway biology (Coskun et al., 2018 — PMID: 30133078).

History

The GLP-2T class emerged from research efforts to simultaneously engage both incretin receptor systems with a single molecule, investigating whether dual-agonist activity could produce synergistic metabolic effects compared to single-receptor agonists. Research characterized the compound’s balanced activity profile at both receptors, with particular focus on its pharmacodynamic properties in preclinical metabolic models (Min & Bain, 2021).

Structure & Molecular Data

CAS Number	2023788-19-2
Molecular Formula	C₂₂₅H₃₄₈N₄₈O₆₈
Molecular Weight	4,813.53 g/mol
Amino Acid Count / Structure	39-amino-acid dual agonist peptide
PubChem CID	156588324
Sequence	Modified 39-residue synthetic dual agonist peptide with Aib substitution and C20 fatty-acid diacid side chain for dual receptor activity and extended half-life
Appearance	Lyophilized white powder
Storage	Store at -20°C. Protect from light and moisture.
Solubility	Soluble in sterile water and bacteriostatic water

 

Compound Class & Mechanism

GLP-2T acts as a balanced co-agonist at both the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R), with research documenting activity profiles that include partial agonism at GLP-1R and full agonism at GIPR in preclinical models. Both receptor systems couple to Gs protein-mediated cAMP-PKA signaling, with downstream effects on insulin secretion, glucagon regulation, and central appetite pathways.

Research has documented pharmacodynamic effects in preclinical models associated with enhanced pancreatic beta-cell signaling, modulation of adipose tissue pathways via GIPR activation, and central appetite signaling through GLP-1R engagement. The C20 fatty-acid diacid side chain and Aib substitution provide DPP-IV resistance and albumin binding, extending the functional half-life for weekly research administration protocols (Frias et al., 2021 — PMID: 34170647).

Research Findings

The GLP-2T-class reference compound has been investigated in preclinical and clinical research spanning metabolic pathway research, body composition research, and cardiovascular pathway studies. Published research has documented findings in the following domains:

Key Research Areas

• Dual Incretin Receptor Research: GIPR/GLP-1R balanced co-agonism pharmacology
• Metabolic Pathway Research: glucose homeostasis and HbA1c-associated research endpoints
• Body Composition Research: hypothalamic satiety and adipose tissue research
• Cardiovascular Pathway Research: cardiovascular research in preclinical models

Collectively, the GLP-2T-class reference compound has been established as a landmark research tool for investigating dual incretin receptor pharmacology and the combined pharmacodynamic effects of GIPR and GLP-1R co-activation in preclinical research environments (Willard et al., 2020).

Research Context

Researchers study G2-T as a reference compound for dual-receptor agonist pharmacology, particularly to investigate the synergistic effects of simultaneous GIPR and GLP-1R engagement. The compound’s balanced profile distinguishes it from single-receptor incretin research compounds.

References

Coskun T. et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Molecular Metabolism. PMID: 30133078

Min T., Bain SC. (2021). The role of [GLP-2T], dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes. Diabetes Therapy.

Frias JP. et al. (2021). [GLP-2T] versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). NEJM. PMID: 34170647

Willard FS. et al. (2020). [GLP-2T] is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight.

Jastreboff AM. et al. (2022). [GLP-2T] once weekly for the treatment of obesity (SURMOUNT-1). NEJM.

Rosenstock J. et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist [GLP-2T] in patients with type 2 diabetes (SURPASS-1). Lancet.

 

Regulatory & Legal Notice

REGULATORY & LEGAL NOTICE Intended Use. This product is sold exclusively as a research chemical for use in controlled laboratory settings by qualified scientific professionals. It is intended solely for in vitro research, analytical standards, and non-clinical preclinical experimentation. The product is not a drug, dietary supplement, cosmetic, food product, or consumer article of any kind. Prohibited Uses. This product is NOT for use in humans, NOT for veterinary use, NOT for in vivo use in any species, NOT for diagnostic use, NOT for therapeutic use, NOT for food or agricultural use, and NOT for compounding into any preparation intended for administration to humans or animals. Qualified Professionals Only. Purchasers represent that they are qualified scientific professionals, licensed researchers, or authorized personnel at a research institution, and that this product will be handled in accordance with all applicable institutional, federal, state, and local regulations governing research chemicals. Regulatory Notice. The statements made regarding this product have not been evaluated by the U.S. Food and Drug Administration. This product has not been approved by the FDA for any therapeutic, diagnostic, or preventive use. Not a Compounding or Outsourcing Facility. Sirius Molecules is a research chemical supplier. Sirius Molecules is not a compounding pharmacy or outsourcing facility as defined under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Legal Compliance. Purchasers are solely responsible for ensuring that their acquisition, possession, handling, and use of this product complies with all applicable laws and regulations in their jurisdiction.